Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial
Source: View publication →
The PREVAIL trial demonstrated that while left atrial appendage closure with the Watchman device did not meet the prespecified noninferiority criteria for overall efficacy against warfarin, it achieved noninferiority for late ischemic events and showed significantly improved procedural safety compared to earlier studies.
Key Findings
Study Design
Study Limitations
Clinical Significance
PREVAIL was instrumental in confirming that LAA occlusion could be performed safely, effectively neutralizing the major critique of the earlier PROTECT AF trial which had a high rate of procedural complications. Although the trial missed one of its composite noninferiority endpoints, the absolute rates of stroke and systemic embolism were numerically low and comparable to well-managed warfarin therapy. This established the Watchman device as a reasonable, safe alternative for stroke prevention in patients with nonvalvular atrial fibrillation who have an appropriate rationale to avoid chronic oral anticoagulation, ultimately securing FDA approval for the device in 2015.
Historical Context
The concept of LAA occlusion gained serious traction with the PROTECT AF trial (2009), which demonstrated noninferiority to warfarin but revealed an alarming periprocedural complication rate (mostly pericardial effusions and procedural strokes). This safety signal prompted the FDA to mandate a second, confirmatory trial—PREVAIL. Conducted entirely in the US and specifically designed to assess whether improved operator training and procedural techniques could mitigate the early hazard, PREVAIL's primary mission was proving procedural safety. By drastically reducing complications, PREVAIL validated the modern era of structural interventions for stroke prevention in AFib.
Guided Discussion
High-yield insights from every perspective
Why is the left atrial appendage specifically targeted for stroke prevention in nonvalvular atrial fibrillation, and what is the anatomical rationale for using a device like Watchman instead of systemic anticoagulation?
Key Response
Tests basic understanding of LAA anatomy as the primary source of thrombus in nonvalvular AF (accounting for >90% of cases) due to blood stasis, contrasting with valvular AF where thrombi can form elsewhere in the atria. It highlights the mechanical vs. pharmacological approach to stroke prevention.
Given that the PREVAIL trial did not meet its primary overall efficacy non-inferiority endpoint against warfarin, in which specific patient populations would you clinically justify recommending a Watchman device today?
Key Response
Encourages applying trial data to clinical decision-making. Residents must recognize that despite missing the primary efficacy endpoint, the reduction in late ischemic events and improved procedural safety make LAAC appropriate for patients with high bleeding risk or strict contraindications to long-term oral anticoagulation.
How does the implant success rate and procedural complication rate in PREVAIL compare to the earlier PROTECT AF trial, and what does this difference illustrate about the learning curve and operator volume in structural heart interventions?
Key Response
Fellows need to evaluate procedural data contextually. PREVAIL showed a significant drop in pericardial effusions and procedure-related strokes compared to PROTECT AF, highlighting the importance of operator experience, device iterations, and refined techniques in the evolution of structural cardiology.
When counseling a patient on the PREVAIL data, how do you balance the failure to achieve formal non-inferiority for overall efficacy with the achieved non-inferiority for late ischemic events to facilitate shared decision-making?
Key Response
Attendings must navigate complex, mixed trial results with patients. The discussion should focus on translating the nuances of early periprocedural risk versus long-term bleeding reduction into patient-centered outcomes, establishing acceptable trade-offs based on individual patient values and bleeding history.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The PREVAIL trial utilized a Bayesian statistical design to incorporate prior data from the PROTECT AF trial. What are the methodological advantages and potential bias risks of using Bayesian adaptive designs with informative priors in regulatory device trials?
Key Response
Challenges the researcher to critique statistical modeling. Using informative priors can increase statistical power and reduce required sample sizes, but it risks carrying over biases or assumptions from earlier trials, which is particularly problematic when procedural safety dynamics or patient populations are shifting between the trials.
From an editorial perspective, how should a journal handle the publication of a non-inferiority trial where the primary efficacy endpoint is formally missed, but secondary or 'late' endpoints are highlighted as successes? What safeguards prevent outcome reporting bias or spin in the abstract?
Key Response
Focuses on peer-review stringency. A rigorous reviewer would flag the emphasis on secondary endpoints (late ischemia) when the primary endpoint failed, assessing whether the manuscript's tone and abstract conclusions objectively reflect the statistical reality without misleading clinical practitioners.
Considering PREVAIL's mixed efficacy results and its use of warfarin as a control, how should current ACC/AHA guidelines grade the recommendation for LAA closure in patients with nonvalvular AF in the modern era where Direct Oral Anticoagulants (DOACs) are the standard of care?
Key Response
Committees must weigh historical evidence against the current standard-of-care. Because PREVAIL compared Watchman to warfarin rather than DOACs, current guidelines (e.g., 2019 AHA/ACC/HRS) appropriately assign LAAC a Class IIb recommendation, restricting it primarily to patients with high stroke risk who have poor suitability for any long-term anticoagulation.
Clinical Landscape
Noteworthy Related Trials
PROTECT AF Trial
Tested
Watchman left atrial appendage closure device
Population
Patients with non-valvular atrial fibrillation eligible for warfarin
Comparator
Warfarin
Endpoint
Composite of stroke, systemic embolism, and cardiovascular or unexplained death
PRAGUE-17 Trial
Tested
Percutaneous left atrial appendage closure
Population
Patients with non-valvular atrial fibrillation at high risk for stroke and bleeding
Comparator
Direct oral anticoagulants (DOACs)
Endpoint
Composite of stroke, TIA, systemic embolism, cardiovascular death, clinically relevant bleeding, or procedure/device-related complications
Amulet IDE Trial
Tested
Amplatzer Amulet LAA occluder
Population
Patients with non-valvular atrial fibrillation at increased risk of stroke
Comparator
Watchman LAA occluder
Endpoint
Composite of ischemic stroke or systemic embolism
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis